Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging.

Reiman EM, Chen K, Langbaum JB, Lee W, Reschke C, Bandy D, Alexander GE, Caselli RJ.

Neuroimage. 2010 Jan 1;49(1):169-76. doi: 10.1016/j.neuroimage.2009.07.025. Epub 2009 Jul 23.

2.

Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention.

Vanitallie TB.

Metabolism. 2013 Jan;62 Suppl 1:S30-3. doi: 10.1016/j.metabol.2012.08.024. Epub 2012 Sep 26. Review.

PMID:
23021038
3.

Linking brain imaging and genomics in the study of Alzheimer's disease and aging.

Reiman EM.

Ann N Y Acad Sci. 2007 Feb;1097:94-113. Review.

PMID:
17413015
4.

Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.

Chételat G, Fouquet M.

Rev Neurol (Paris). 2013 Oct;169(10):729-36. doi: 10.1016/j.neurol.2013.07.025. Epub 2013 Sep 6. Review.

5.

Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease.

Poirier J, Miron J, Picard C, Gormley P, Théroux L, Breitner J, Dea D.

Neurobiol Aging. 2014 Sep;35 Suppl 2:S3-10. doi: 10.1016/j.neurobiolaging.2014.03.037. Epub 2014 May 15. Review.

6.

Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.

Chen Z, Zhong C.

Prog Neurobiol. 2013 Sep;108:21-43. doi: 10.1016/j.pneurobio.2013.06.004. Epub 2013 Jul 11. Review.

7.

Imaging and cognitive reserve studies predict dementia in presymptomatic Alzheimer's disease subjects.

Ferrari C, Nacmias B, Bagnoli S, Piaceri I, Lombardi G, Pradella S, Tedde A, Sorbi S.

Neurodegener Dis. 2014;13(2-3):157-9. doi: 10.1159/000353690. Epub 2013 Aug 7. Review.

PMID:
23942061
8.

Cerebral blood flow and metabolic abnormalities in Alzheimer's disease.

Matsuda H.

Ann Nucl Med. 2001 Apr;15(2):85-92. Review.

PMID:
11448080
9.

Alzheimer's Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function.

Di Battista AM, Heinsinger NM, Rebeck GW.

Curr Alzheimer Res. 2016;13(11):1200-1207. Review.

PMID:
27033053
10.

Brain-imaging surrogate markers for detection and prevention of age-related memory loss.

Small GW.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):17-21. Review.

PMID:
12212776
11.

APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging.

Bookheimer S, Burggren A.

Annu Rev Clin Psychol. 2009;5:343-62. doi: 10.1146/annurev.clinpsy.032408.153625. Review.

12.

Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes.

Mosconi L, Berti V, Swerdlow RH, Pupi A, Duara R, de Leon M.

Hum Genomics. 2010 Feb;4(3):170-93. Review.

13.

The concept of FDG-PET endophenotype in Alzheimer's disease.

During EH, Osorio RS, Elahi FM, Mosconi L, de Leon MJ.

Neurol Sci. 2011 Aug;32(4):559-69. doi: 10.1007/s10072-011-0633-1. Epub 2011 Jun 1. Review.

14.

Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.

Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F, Tariot PN.

J Alzheimers Dis. 2011;26 Suppl 3:321-9. doi: 10.3233/JAD-2011-0059. Review.

15.

Brain fuel metabolism, aging, and Alzheimer's disease.

Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E, Tremblay S, Castellano A, Pifferi F, Bocti C, Paquet N, Begdouri H, Bentourkia M, Turcotte E, Allard M, Barberger-Gateau P, Fulop T, Rapoport SI.

Nutrition. 2011 Jan;27(1):3-20. doi: 10.1016/j.nut.2010.07.021. Epub 2010 Oct 29. Review.

16.
17.

Statins and dementia.

Kuller LH.

Curr Atheroscler Rep. 2007 Aug;9(2):154-61. Review.

PMID:
17877925
18.

Alzheimer disease--no target for statin treatment. A mini review.

Hoyer S, Riederer P.

Neurochem Res. 2007 Apr-May;32(4-5):695-706. Epub 2006 Oct 25. Review.

PMID:
17063393
19.

Alzheimer's disease and cholesterol: the fat connection.

Canevari L, Clark JB.

Neurochem Res. 2007 Apr-May;32(4-5):739-50. Epub 2006 Dec 27. Review.

PMID:
17191138
20.

Hypometabolism as a therapeutic target in Alzheimer's disease.

Costantini LC, Barr LJ, Vogel JL, Henderson ST.

BMC Neurosci. 2008 Dec 3;9 Suppl 2:S16. doi: 10.1186/1471-2202-9-S2-S16. Review.

Supplemental Content

Support Center